IST-3: thrombolysis with intravenous Alteplase for acute ischaemic stroke does not affect survival at 18 months


Few data are available from randomised trials about the effect of thrombolysis with Alteplase ( TPA; Activase, Actilyse ) on long-term functional outcome in patients who have had acute ischaemic stroke and no trial has reported effects on health-related quality of life. A secondary objective of the third International Stroke Trial ( IST-3 ) was to assess the effect of thrombolysis on such outcomes at 18 months.

In this open-label, international, multicentre, randomised, controlled trial, 3035 patients with ischaemic stroke from 12 countries were randomly allocated within 6 h of onset via a secure central system to either intravenous Alteplase ( 0.9 mg/kg; n=1515 ) plus standard care or standard care alone ( control; n=1520 ). 2348 patients were scheduled for 18-month follow-up.
For the main analysis, survivors were assessed at 18 months with the Oxford handicap scale ( OHS; the primary outcome was the adjusted odds of OHS score 0-2 ). Researchers also used the EuroQoL ( EQ ) instrument and asked questions about overall functioning and living circumstances.
Researchers analysed the OHS and the five EQ domains by ordinal logistic regression and calculated the mean difference between treatment groups in EQ utility index and visual analogue scale score. Analyses were adjusted for key baseline prognostic factors.

At 18 months, 408 ( 34.9% ) of 1169 patients in the Alteplase group versus 414 ( 35.1% ) of 1179 in the control group had died ( p=0.85 ). 391 ( 35.0% ) of 1117 patients versus 352 ( 31.4% ) of 1122 had an OHS score of 0-2 ( adjusted odds ratio [ OR ] 1.28; p=0.024 ).

Treatment was associated with a favourable shift in the distribution of OHS grades ( adjusted common OR=1.30; p=0.002 ).

Alteplase treatment was associated with significantly higher overall self-reported health ( adjusted mean difference in EQ utility index 0.060; p=0.019 ).

The differences between the groups in visual analogue scale score and the proportion living at home were not significant.

IST-3 ( the third International Stroke Trial ) has provided evidence that thrombolysis with intravenous Alteplase for acute ischaemic stroke does not affect survival, but does lead to statistically significant, clinically relevant improvements in functional outcome and health-related quality of life that are sustained for at least 18 months. ( Xagena )

The IST-3 collaborative group, The Lancet Neurology 2013; 12: 768-776

XagenaMedicine_2013



Indietro

Altri articoli

The aim of a study was to identify whether particular subgroups of patients had an unacceptably high risk of symptomatic...


In patients with acute ischemic stroke caused by a proximal intracranial arterial occlusion, intraarterial treatment is highly effective for emergency...


Uric acid is an antioxidant with neuroprotective effects in experimental models of stroke. Researchers have assessed whether uric acid therapy...


The SAINT I ( Stroke Acute Ischemic NXY-059 Treatment ) trial, published in the New England Journal of Medicine, has...


Patient enrolment into TROICA, a randomized, double-blind, placebo-controlled Phase III clinical study of the single-bolus thrombolytic Metalyse ( Tenecteplase )...


A Johns Hopkins study has shown that patients treated for intracerebral hemorrhage, survived more often if given 1 milligram instead...


Patient enrolment into TROICA, a randomized, double-blind, placebo-controlled Phase III clinical study of the single-bolus thrombolytic Metalyse ( Tenecteplase )...